JP6389950B2 - 細菌株を含む組成物 - Google Patents

細菌株を含む組成物 Download PDF

Info

Publication number
JP6389950B2
JP6389950B2 JP2017501359A JP2017501359A JP6389950B2 JP 6389950 B2 JP6389950 B2 JP 6389950B2 JP 2017501359 A JP2017501359 A JP 2017501359A JP 2017501359 A JP2017501359 A JP 2017501359A JP 6389950 B2 JP6389950 B2 JP 6389950B2
Authority
JP
Japan
Prior art keywords
composition
asthma
disease
composition according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017501359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502551A (ja
Inventor
ジョージ グラント
ジョージ グラント
アンジェラ マーガレット パターソン
アンジェラ マーガレット パターソン
イムケ ムルダー
イムケ ムルダー
ショーニン マックルスキー
ショーニン マックルスキー
エマ ラフティス
エマ ラフティス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4D Pharma Research Ltd
Original Assignee
4D Pharma Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1510469.8A external-priority patent/GB201510469D0/en
Priority claimed from GBGB1520628.7A external-priority patent/GB201520628D0/en
Priority claimed from GBGB1604566.8A external-priority patent/GB201604566D0/en
Application filed by 4D Pharma Research Ltd filed Critical 4D Pharma Research Ltd
Publication of JP2018502551A publication Critical patent/JP2018502551A/ja
Application granted granted Critical
Publication of JP6389950B2 publication Critical patent/JP6389950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2017501359A 2015-06-15 2016-06-15 細菌株を含む組成物 Active JP6389950B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1510469.8 2015-06-15
GBGB1510469.8A GB201510469D0 (en) 2015-06-15 2015-06-15 Compostions comprising bacterial strains
GB1520628.7 2015-11-23
GBGB1520628.7A GB201520628D0 (en) 2015-11-23 2015-11-23 Compositions comprising bacterial strains
GB1604566.8 2016-03-17
GBGB1604566.8A GB201604566D0 (en) 2016-03-17 2016-03-17 Compositions comprising bacterial strains
PCT/GB2016/051773 WO2016203220A1 (en) 2015-06-15 2016-06-15 Compositions comprising bacterial strains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018153877A Division JP2018199695A (ja) 2015-06-15 2018-08-20 細菌株を含む組成物

Publications (2)

Publication Number Publication Date
JP2018502551A JP2018502551A (ja) 2018-02-01
JP6389950B2 true JP6389950B2 (ja) 2018-09-12

Family

ID=56194512

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017501359A Active JP6389950B2 (ja) 2015-06-15 2016-06-15 細菌株を含む組成物
JP2018153877A Pending JP2018199695A (ja) 2015-06-15 2018-08-20 細菌株を含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018153877A Pending JP2018199695A (ja) 2015-06-15 2018-08-20 細菌株を含む組成物

Country Status (32)

Country Link
US (4) US10493112B2 (enExample)
EP (4) EP3884953A1 (enExample)
JP (2) JP6389950B2 (enExample)
KR (1) KR20180012845A (enExample)
CN (2) CN108738311B (enExample)
AU (2) AU2016278069B2 (enExample)
BR (1) BR112017025003A2 (enExample)
CA (2) CA2988686C (enExample)
CL (1) CL2017003191A1 (enExample)
CO (1) CO2017013231A2 (enExample)
CY (3) CY1122467T1 (enExample)
DK (3) DK3369425T3 (enExample)
EA (1) EA201890049A1 (enExample)
ES (3) ES2863913T3 (enExample)
HR (3) HRP20192057T1 (enExample)
HU (3) HUE046221T2 (enExample)
IL (1) IL255783B2 (enExample)
LT (3) LT3369425T (enExample)
MA (1) MA41060B1 (enExample)
MD (3) MD3369425T2 (enExample)
ME (2) ME03784B (enExample)
MX (1) MX2017016564A (enExample)
PE (1) PE20180266A1 (enExample)
PL (3) PL3369425T3 (enExample)
PT (3) PT3204025T (enExample)
RS (3) RS59558B1 (enExample)
SG (2) SG10201912321RA (enExample)
SI (3) SI3549592T1 (enExample)
SM (3) SMT202000227T1 (enExample)
TW (2) TWI739746B (enExample)
WO (1) WO2016203220A1 (enExample)
ZA (1) ZA201707774B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
PT3065748T (pt) 2014-12-23 2018-02-28 4D Pharma Res Ltd Uma estirpe de bacteroides thetaiotaomicron e o seu uso na redução da inflamação
BR112017013274A2 (pt) 2014-12-23 2018-02-06 4D Pharma Research Limited polipeptídeo e imunomodulação
PL3307288T3 (pl) 2015-06-15 2019-12-31 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
PT3360559T (pt) 2015-06-15 2020-01-06 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
SMT201900588T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
HUE036362T2 (hu) 2015-11-20 2018-07-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3313423T3 (pl) 2016-03-04 2019-09-30 4D Pharma Plc Kompozycje zawierające szczepy bakteryjne blautia do leczenia nadwrażliwości trzewnej
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
MX2018015522A (es) 2016-06-14 2019-07-12 Vedanta Biosciences Inc Tratamiento de infeccion por clostridium difficile.
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3606325B1 (en) 2017-04-03 2024-09-04 Gusto Global, LLC Rational design of microbial-based biotherapeutics
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HUE059249T2 (hu) 2017-06-14 2022-11-28 4D Pharma Res Limited Baktériumtörzseket tartalmazó készítmények
PT3638271T (pt) 2017-06-14 2021-01-05 4D Pharma Res Ltd Composições contendo estirpes bacterianas
GB201806779D0 (en) * 2018-04-25 2018-06-06 4D Pharma Res Ltd Compositions comprising bacterial strains
AU2018285445B2 (en) * 2017-06-14 2020-03-26 Cj Bioscience, Inc. Compositions comprising bacterial strains
AU2019267170A1 (en) 2018-05-11 2021-01-07 4D Pharma Research Limited Compositions comprising bacterial strains
AU2019321681A1 (en) 2018-08-17 2021-02-25 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
CN110917219B (zh) * 2018-09-04 2021-09-07 星聚樊生物科技有限公司 戈氏副拟杆菌用于制备预防和/或治疗慢性阻塞性肺病的医药组成物的用途
TWI688394B (zh) * 2018-09-04 2020-03-21 星聚樊生物科技有限公司 戈氏副擬桿菌用於預防或治療慢性阻塞性肺病之用途
TWI721549B (zh) * 2018-09-04 2021-03-11 星聚樊生物科技有限公司 戈氏副擬桿菌用於治療慢性腎臟疾病之用途
MA53617A (fr) * 2018-09-10 2021-07-21 Riken Composition pour inhiber l'activité de la trypsine, contenant, en tant que principe actif, une bactérie appartenant au genre paraprevotella
KR102269450B1 (ko) * 2018-09-14 2021-06-25 연세대학교 산학협력단 장내 병원성 세균에 대한 항균 활성 균주 및 이를 포함하는 병원성 장내 세균 유발성 질환의 예방 또는 치료용 약학적 조성물
AU2019351019B2 (en) * 2018-09-27 2024-09-19 Research Development Foundation Methods and probiotic compositions for the treatment of bone disorders
US11116803B2 (en) * 2018-10-31 2021-09-14 Multistars Biotechnology Company Limited Method of treating lung cancer using Parabacteroides goldsteinii
CA3117865A1 (en) 2018-11-02 2020-05-07 4D Pharma Research Limited Compositions comprising bacterial strains
WO2020120717A1 (en) * 2018-12-12 2020-06-18 4D Pharma Research Limited Compositions comprising parabacteroides bacterial strains for treating cancer
CN110172427A (zh) * 2019-06-11 2019-08-27 江南大学 一种提高狄氏副拟杆菌冻干存活率的方法及应用
JP7761556B2 (ja) * 2019-09-18 2025-10-28 リサーチ ディベロップメント ファウンデーション 代謝性疾患および障害を治療するための方法およびプロバイオティック組成物
WO2021221110A1 (ja) * 2020-04-29 2021-11-04 学校法人慶應義塾 Ｔｈ１細胞及び／又はＴｈ１７細胞の増殖又は活性化を誘導する小腸内細菌
CN112410242A (zh) * 2020-08-25 2021-02-26 上海市第十人民医院 一株分离自直肠癌肿瘤组织的狄氏副拟杆菌株及其应用
EP3967314A1 (en) * 2020-09-15 2022-03-16 Institut national de recherche pour l'agriculture l'alimentation et l'environnement Parabacteroides distasonis strains for use thereof in the treatment and prevention of gastrointestinal diseases and of disorders associated with gastrointestinal diseases
CN114908022A (zh) * 2022-06-17 2022-08-16 中国海洋大学 一种副拟杆菌属菌株及其培养方法和应用
AU2024327567A1 (en) * 2023-08-22 2026-01-08 International N&H Denmark Aps Methods and compositions for immune system regulation
CN120041316A (zh) * 2023-11-27 2025-05-27 慕恩（广州）生物科技有限公司 副拟杆菌属菌株、培养物、菌剂及其应用

Family Cites Families (361)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
EP0433299B1 (en) 1988-08-02 1998-05-06 Gastro Services Pty. Limited (ACN 002 994 890) Treatment of gastro-intestinal disorders
KR100225087B1 (ko) 1990-03-23 1999-10-15 한스 발터라벤 피타아제의 식물내 발현
ATE118545T1 (de) 1990-05-09 1995-03-15 Novo Nordisk As Eine ein endoglucanase enzym enthaltende zellulasezubereitung.
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5443951A (en) 1992-07-20 1995-08-22 Kabushiki Kaisha Yakult Honsha Species-specific oligonucleotides for bifidobacteria and a method of detection using the same
JPH08504327A (ja) 1992-12-10 1996-05-14 ギスト ブロカデス ナムローゼ フェンノートシャップ 糸状菌における異種タンパクの生産
US5741665A (en) 1994-05-10 1998-04-21 University Of Hawaii Light-regulated promoters for production of heterologous proteins in filamentous fungi
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM823094A0 (en) 1994-09-16 1994-10-13 Goodman Fielder Limited Probiotic compositions
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
RU2078815C1 (ru) 1995-01-17 1997-05-10 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Штамм бактерий bifidobacterium breve, используемый для получения бактерийных лечебно-профилактических бифидосодержащих препаратов
JPH08259450A (ja) 1995-03-17 1996-10-08 Nichinichi Seiyaku Kk インターフェロン産生増強剤
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
AUPN698495A0 (en) 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
SE508045C2 (sv) 1996-02-26 1998-08-17 Arla Ekonomisk Foerening Adhesionsinhibitorer, preparat innehållande desamma och förfarande för framställning därav
AUPN881396A0 (en) 1996-03-20 1996-04-18 Arnott's Biscuits Limited Enhancement of microbial colonization of the gastrointestinal tract
US6348452B1 (en) 1996-03-20 2002-02-19 The University Of New South Wales Alteration of microbial populations in the gastrointestinal tract
AU2152897A (en) 1996-03-27 1997-10-17 Novo Nordisk A/S Alkaline protease deficient filamentous fungi
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
AU6773598A (en) 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
SE511524C2 (sv) 1997-06-02 1999-10-11 Essum Ab Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning för bekämpning av patogena tarmbakterier
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
DE19826928A1 (de) 1998-06-17 1999-12-23 Novartis Consumer Health Gmbh Arzneimittel, lebensfähige anaerobe Bakterien enthaltend, die die Sulfatreduktion sulfatreduzierender Bakterien hemmen
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7090973B1 (en) 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
CA2395343C (en) 2000-02-08 2009-06-30 F. Hoffmann-La Roche Ag Use of acid-stable proteases in animal feed
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AU2002226984A1 (en) 2000-11-27 2002-06-03 Astrazeneca Ab Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon
DE10101793A1 (de) 2001-01-17 2002-08-01 Manfred Nilius Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen
EP1227152A1 (en) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
KR100437497B1 (ko) 2001-03-07 2004-06-25 주식회사 프로바이오닉 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제
EP1243273A1 (en) 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
EP1260227A1 (en) 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
PE20030284A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
US20040241149A1 (en) 2001-09-05 2004-12-02 Claudio De Simone Use of unmethylatd cpg
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
JP2005518195A (ja) 2001-11-27 2005-06-23 ワシントン・ユニバーシティ 治療用タンパク質および治療方法
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
DE10206995B4 (de) 2002-02-19 2014-01-02 Orthomol Pharmazeutische Vertriebs Gmbh Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
JP2003261453A (ja) 2002-03-11 2003-09-16 Nippon Berumu Kk Ｅ．フェカリスからなる抗腫瘍剤及び放射線防護剤
DK1565547T4 (da) 2002-06-28 2013-01-14 Biosearch S A Probiotiske stammer, en fremgangsmåde til selektion deraf, præparater deraf samt anvendelse deraf
US20040005304A1 (en) 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1481681A1 (en) 2003-05-30 2004-12-01 Claudio De Simone Lactic acid bacteria combination and compositions thereof
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
AU2003247193A1 (en) 2003-07-23 2005-02-04 M.D.Lab Corp. Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus
US7485325B2 (en) 2003-08-06 2009-02-03 Gayle Dorothy Swain Animal food supplement compositions and methods of use
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
WO2005030133A2 (en) 2003-09-22 2005-04-07 Yale University Treatment with agonists of toll-like receptors
GB0323039D0 (en) 2003-10-01 2003-11-05 Danisco Method
RU2373769C2 (ru) 2003-10-24 2009-11-27 Н.В. Нютрисиа Синбиотическая композиция для детей
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
WO2005058335A1 (en) 2003-12-17 2005-06-30 N.V. Nutricia Lactic acid producing bacteria and lung function
ES2235642B2 (es) 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
EP1727894A1 (en) 2004-03-22 2006-12-06 Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Cellular and viral inactivation
JP2007535924A (ja) 2004-05-07 2007-12-13 − グスタフ ユングレン、ハンス ワクチン用アジュバントとしてのフラジェリンの使用
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
NZ586338A (en) 2004-06-07 2012-02-24 Qu Biolog Inc Bacterial compositions for the treatment of cancer
PT1629850E (pt) 2004-08-24 2007-08-14 Nutricia Nv Composição nutricional que compreende a administração de oligossacarídeos indigeríveis
US20060062742A1 (en) 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for reduction of human malodor
KR100468522B1 (ko) 2004-10-12 2005-01-31 주식회사 프로바이오닉 코로나바이러스와 돼지 써코바이러스 2형의 생육을 억제하는 신규한 내산성 프로바이오틱 엔테로코커스훼시움 프로바이오-63
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
ITMI20042189A1 (it) 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
ATE526836T1 (de) 2005-02-28 2011-10-15 Nutricia Nv Nährstoffzusammensetzung mit probiotika
WO2006102536A2 (en) 2005-03-23 2006-09-28 University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
WO2006102350A1 (en) 2005-03-23 2006-09-28 Washington University In St. Louis The use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
JP2006265212A (ja) 2005-03-25 2006-10-05 Institute Of Physical & Chemical Research Ｉｌ−２１産生誘導剤
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
EP1714660A1 (en) 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
ATE549394T1 (de) 2005-04-26 2012-03-15 Teagasc Agric Food Dev Authori Für tiere geeignete probiotische zusammensetzung
US7572474B2 (en) 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8075934B2 (en) 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
JP2007084533A (ja) 2005-08-24 2007-04-05 Prima Meat Packers Ltd 免疫応答調節組成物及び該組成物を有効成分とする食品
US7625704B2 (en) 2005-08-31 2009-12-01 Fred Hutchinson Cancer Research Center Methods and compositions for identifying bacteria associated with bacteria vaginosis
BRPI0615297A2 (pt) 2005-09-01 2011-05-17 Schering Corp antagonistas de il-23 e de il-17 para tratar doença inflamatória ocular auto-imune e seus usos
US20090028840A1 (en) 2005-09-23 2009-01-29 Gwangju Institute Of Sciecne And Technology Compositions For Preventing Or Treating Arthritis Comprising Lactic Acid Bacteria and Collangen As Active Ingredients
CA2624964C (en) 2005-10-06 2015-01-06 Nestec S.A. Probiotic enterococci for improved immunity
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
AU2006306241B9 (en) 2005-10-24 2012-03-08 Nestec S.A. Dietary fiber formulation and method of administration
JP2007116991A (ja) 2005-10-28 2007-05-17 Eternal Light General Institute Inc 機能性食品
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
EP1957449A1 (en) 2005-12-01 2008-08-20 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
WO2007098371A2 (en) 2006-02-16 2007-08-30 Wayne State University Use of flagellin to prevent and treat gram negative bacterial infection
US20080260898A1 (en) 2006-03-17 2008-10-23 Marko Stojanovic Compositions comprising probiotic and sweetener components
JP5031249B2 (ja) 2006-03-22 2012-09-19 学校法人北里研究所 炎症抑制作用のある菌体含有組成物
WO2007126990A2 (en) 2006-03-29 2007-11-08 Nestec S.A. Dietary supplements containing probiotics
CA2652559A1 (en) 2006-05-18 2007-11-29 Biobalance Llc Biotherapeutic compositions and uses thereof
WO2007140230A2 (en) 2006-05-26 2007-12-06 Nestec S.A. Methods of use and nutritional compositions of touchi extract
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
ES2525223T3 (es) 2006-08-04 2014-12-19 Shs International Ltd. Fórmula sin proteínas
WO2008031438A2 (en) 2006-09-13 2008-03-20 Region Hovedstaden V/Gentofte Hospital Treatment of asthma, eczema and/or allergy using non-pathogenic organisms
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
KR101170283B1 (ko) 2006-10-27 2012-07-31 화이자 프로덕츠 인코포레이티드 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법
US20080118473A1 (en) 2006-11-01 2008-05-22 The Procter & Gamble Company Methods of treating a respiratory condition comprising probiotic treatment
EP1920782A1 (en) 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
WO2008064489A1 (en) 2006-12-01 2008-06-05 Mcmaster University Probiotics to inhibit inflammation
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
WO2008083157A2 (en) 2006-12-29 2008-07-10 Washington University In St. Louis Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject
JP2008195635A (ja) 2007-02-09 2008-08-28 Crossfield Bio Inc 馬用乳酸菌製剤
GB0703285D0 (en) * 2007-02-20 2007-03-28 Cutler Daniel Retractable covering apparatus
ATE544457T1 (de) 2007-02-28 2012-02-15 Mead Johnson Nutrition Co Verfahren zur behandlung bzw. prävention systemischer entzündungen
WO2008117267A2 (en) 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic bifidobacterium strains
US8557233B2 (en) 2007-03-28 2013-10-15 Alimentary Heath Limited Probiotic bifidobacterium strains
US20080299098A1 (en) 2007-04-24 2008-12-04 Chea-Yun Se Broad-Spectrum Antibacterial and Antifungal Activity of Lactobacillus Johnsonii D115
EP1997499A1 (en) 2007-05-31 2008-12-03 Puleva Biotech, S.A. Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis
EP1997905A1 (en) 2007-06-01 2008-12-03 Friesland Brands B.V. Nucleic acid amplification
EP1997907A1 (en) 2007-06-01 2008-12-03 Friesland Brands B.V. Bifidobacteria
EP1997906A1 (en) 2007-06-01 2008-12-03 Friesland Brands B.V. Lactobacillus
WO2008153377A1 (en) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
ES2611277T3 (es) 2007-06-27 2017-05-08 Laboratorios Ordesa, S.L. Péptidos contra una infección por rotavirus
HUP0700552A2 (en) 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2192909A2 (en) 2007-10-01 2010-06-09 University College Cork-National University of Ireland, Cork Modulation of tissue fatty acid composition of a host by human gut bacteria
WO2009049932A1 (en) 2007-10-20 2009-04-23 Universite De Liege Bifidobacterial species
EP2211879B1 (en) 2007-10-26 2014-05-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
EP2065048A1 (en) 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
EP2356992B1 (en) 2007-12-07 2017-08-16 N.V. Nutricia Bifidobactrium for dust mite allergy
US20100330190A1 (en) 2007-12-17 2010-12-30 Compans Richard W Immunogenic compositions and methods of use thereof
ES2343499B1 (es) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
BRPI0908348A2 (pt) 2008-02-06 2015-07-28 Procter & Gamble Métodos e kits de composições para acentuar a resposta imunológica a uma condição respiratória
EP2103226A1 (en) 2008-03-18 2009-09-23 Friesland Brands B.V. Long-life probiotic food product
ES2594102T3 (es) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
JP2011520435A (ja) 2008-05-13 2011-07-21 グリコトープ ゲーエムベーハー 発酵プロセス
MX2008006546A (es) 2008-05-21 2009-11-23 Sigma Alimentos Sa De Cv Bifidobacteria productora de ácido fólico, composición alimenticia y uso de la bifidobacteria.
CN102940652B (zh) 2008-05-28 2015-03-25 青岛东海药业有限公司 两形真杆菌制剂及其应用
CN101590081A (zh) 2008-05-28 2009-12-02 青岛东海药业有限公司 凸腹真杆菌和两形真杆菌制剂及其应用
US8586029B2 (en) 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
EP2133088A3 (en) 2008-06-09 2010-01-27 Nestec S.A. Rooibos and inflammation
WO2009151315A1 (en) 2008-06-13 2009-12-17 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
WO2009154463A2 (en) 2008-06-20 2009-12-23 Stichting Top Institute Food And Nutrition Butyrate as a medicament to improve visceral perception in humans
EP2138186A1 (en) 2008-06-24 2009-12-30 Nestec S.A. Probiotics, secretory IgA and inflammation
WO2010002241A1 (en) 2008-06-30 2010-01-07 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
KR101017448B1 (ko) 2008-09-18 2011-02-23 주식회사한국야쿠르트 대장의 건강 증진 효능을 갖는 비피도박테리움 롱검 에이취와이8004 및 이를 유효성분으로 함유하는 제품
US8137718B2 (en) 2008-09-19 2012-03-20 Mead Johnson Nutrition Company Probiotic infant products
US20100074870A1 (en) 2008-09-19 2010-03-25 Bristol-Myers Squibb Company Probiotic infant products
KR101057357B1 (ko) 2008-09-22 2011-08-17 광주과학기술원 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
EP2337569A4 (en) 2008-09-25 2013-04-03 Univ New York COMPOSITIONS AND METHODS FOR CHARACTERIZING AND RESTORING THE STOMACH DARM, SKIN AND NOSE MICROBIOTA
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
RU2509478C2 (ru) 2008-12-05 2014-03-20 Нестек С.А. Пробиотическая композиция, предназначенная для младенцев с низкой массой тела при рождении
AU2009328383A1 (en) 2008-12-19 2011-07-07 Nestec S.A. Prevention and treatment of rotavirus diarrhoea
IT1392672B1 (it) 2009-01-12 2012-03-16 Wyeth Consumer Healthcare S P A Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina
MX2011009362A (es) 2009-03-05 2011-09-26 Abbott Lab Proteinas de union a il-17.
JP5710876B2 (ja) 2009-03-26 2015-04-30 クロスフィールドバイオ株式会社 新規ビフィドバクテリウム属微生物およびその利用
US20120142605A1 (en) * 2009-05-05 2012-06-07 Amgen Inc. Methods of treating psoriasis
EP2427499A1 (en) 2009-05-07 2012-03-14 Tate&Lyle Ingredients France SAS Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
CA2761444C (en) 2009-05-11 2018-04-24 Nestec S.A. Lactobacillus johnsonii la1 ncc533 (cncm i-1225) and immune disorders
EP2251022A1 (en) 2009-05-11 2010-11-17 Nestec S.A. Non-replicating micro-organisms and their immune boosting effect
EP2251020A1 (en) 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
KR20100128168A (ko) 2009-05-27 2010-12-07 중앙대학교 산학협력단 공액 리놀레산 생산능이 우수한 신규한 균주
US20100311686A1 (en) 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2010143940A1 (en) 2009-06-12 2010-12-16 N.V. Nutricia Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages
EP2443259A4 (en) 2009-06-16 2012-10-10 Univ Columbia BIOMARKERS ASSOCIATED WITH AUTISM AND USES THEREOF
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
AU2010274941A1 (en) 2009-07-24 2012-02-09 Southwest Regional Pcr, Llc Universal microbial diagnosis, detection, quantification, and specimen-targeted therapy
ES2664724T3 (es) 2009-08-18 2018-04-23 Nestec S.A. Composición nutricional que comprende cepas de Bifidobacterium longum y que reduce los síntomas de alergia alimentaria, especialmente en lactantes y niños
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
AU2010299552A1 (en) 2009-09-23 2012-04-05 Thomas Julius Borody Therapy for enteric infections
EP2308498A1 (en) 2009-09-30 2011-04-13 Nestec S.A. Administration of Bifidobacterium breve during infancy to prevent inflammation later in life
US20120238468A1 (en) 2009-10-05 2012-09-20 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
EP2485742A4 (en) 2009-10-06 2013-03-20 Scott Dorfner ANTIBIOTIC FORMULATIONS WITH REDUCED SIDE EFFECTS ON STOMACH AND DARM
EP2498789B1 (en) 2009-11-11 2016-06-22 Alimentary Health Limited Probiotic bifidobacterium strain
EP2512261A1 (en) 2009-12-18 2012-10-24 Hill's Pet Nutrition, Inc. Pet food compositions including probiotics and methods of manufacture and use thereof
US20150104418A1 (en) 2014-12-18 2015-04-16 Microbios, Inc. Bacterial composition
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
NL2004200C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
JP5737646B2 (ja) 2010-03-24 2015-06-17 森下仁丹株式会社 抗アレルギー剤
EP2552464B1 (en) 2010-03-30 2018-02-28 Assistance Publique - Hôpitaux de Paris Use of bifidobacteria for preventing allergy in breastfed infants
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011149335A1 (en) 2010-05-25 2011-12-01 N.V. Nutricia Immune imprinting nutritional composition
US20130195802A1 (en) 2010-06-01 2013-08-01 Moore Research Enterprises Llc Cellular Constituents From Bacteroides, Compositions Thereof, and Therapeutic Methods Employing Bacteroides or Cellular Constituents Thereof
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
TWI417054B (zh) 2010-06-15 2013-12-01 Jen Shine Biotechnology Co Ltd 新穎糞腸球菌ｌｊｓ－０１及其益生用途
EP2397145A1 (en) 2010-06-18 2011-12-21 Nestec S.A. L. johnsonii La1, B. longum NCC2705 and immune disorders
FR2962045B1 (fr) 2010-07-05 2012-08-17 Bifinove Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
TWI401086B (zh) 2010-07-20 2013-07-11 Univ China Medical 胚芽乳酸桿菌及其用途
RU2722357C2 (ru) 2010-07-26 2020-05-29 Кью Байолоджикс Инк. Иммуногенные противовоспалительные композиции
NZ618935A (en) 2010-08-04 2014-03-28 Karma Medical Prod Co Ltd Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
KR101250463B1 (ko) 2010-10-12 2013-04-15 대한민국 신생아 분변에서 분리한 내산소성 비피도박테리움 롱검 비피더스 유산균 및 이를 이용한 프로바이오틱 조성물
KR20130113476A (ko) 2010-10-27 2013-10-15 ?티백트 에이/에스 인터칼레이터 （ｉｎｔｅｒｃａｌａｔｏｒ） 분자를 포함하는 프로브에 의한 표적 ＤＮＡ 및 ＲＮＡ의 캡쳐
CN102031235B (zh) 2010-11-09 2012-07-25 中国农业大学 一种粪肠球菌anse228及其应用
EP2455092A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
WO2012071380A1 (en) 2010-11-24 2012-05-31 Oragenics, Inc. Use of bacteria to treat and prevent respiratory infections
CN102093967B (zh) 2010-12-02 2013-01-30 中国农业科学院特产研究所 一株水貂源屎肠球菌及其应用
ES2389547B1 (es) 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
EA026524B1 (ru) 2011-01-10 2017-04-28 Общество С Ограниченной Ответственностью "Биолаб 612" Применение агониста toll-подобного рецептора для лечения рака
DK2481299T3 (en) 2011-01-31 2017-02-06 Dr Fischer Gesundheitsprodukte Gmbh BIFIDOBACTERIUM BIFIDUM STREAMS FOR USE IN GASTROINTESTINAL DISEASES
JP5840368B2 (ja) 2011-02-02 2016-01-06 カルピス株式会社 関節炎予防改善用物質
CN103491969A (zh) 2011-02-09 2014-01-01 拉维沃公司 恢复和重建肠道微生物群的合生素组合物
WO2012122478A1 (en) 2011-03-09 2012-09-13 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
WO2012140636A1 (en) 2011-04-11 2012-10-18 Alimentary Health Limited A probiotic formulation
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
CN103781487A (zh) 2011-04-20 2014-05-07 米科生物公司 用于增强免疫应答的组合物和方法
WO2012158517A1 (en) 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
CN103561575A (zh) * 2011-05-23 2014-02-05 华盛顿州立大学研究基金会 光合色素稳定剂在水果和蔬菜中调控成熟和质量的用途
KR20120133133A (ko) 2011-05-30 2012-12-10 한국 한의학 연구원 생약 추출물 또는 이의 유산균 발효물을 포함하는 호흡기 질환의 예방 또는 치료용 조성물
US20140171339A1 (en) 2011-06-06 2014-06-19 The University Of North Carolina At Chapel Hill Methods and kits for detecting adenomas, colorectal cancer, and uses thereof
GB201110095D0 (en) 2011-06-15 2011-07-27 Danisco Method of treatment
JP2013005759A (ja) 2011-06-24 2013-01-10 Kyodo Milk Industry Co Ltd マウス腸内菌叢の推測方法
US20140128585A1 (en) 2011-07-07 2014-05-08 Nagaoka Perfumery Co., Ltd. Fructose absorption inhibitor
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
US20130017999A1 (en) 2011-07-14 2013-01-17 Marc Fremont Methods and Compositions for Evaluating and/or Treating Chronic Immune Diseases
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
CN102304483A (zh) 2011-08-12 2012-01-04 北京金泰得生物科技股份有限公司 一株饲用屎肠球菌及其应用
KR101261872B1 (ko) 2011-08-23 2013-05-14 대한민국 (식품의약품안전처장) 장내 미생물 효소복합체 및 이의 제조방법
EP2744890A4 (en) * 2011-09-14 2015-07-08 Univ Kingston METHOD FOR TREATING DISORDERS OF THE MAGENDAR SYSTEM
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
PL2750682T3 (pl) 2011-10-11 2016-10-31 Kompozycja zawierająca hodowaną beztlenowo ludzką mikroflorę jelitową
CN103082292B (zh) 2011-11-02 2015-03-04 深圳华大基因研究院 罗斯氏菌(Roseburia)在治疗和预防肥胖相关疾病中的应用
CN102373172B (zh) 2011-11-03 2013-03-20 北京龙科方舟生物工程技术有限公司 一株屎肠球菌及其应用
EP4477750A3 (en) 2011-12-01 2025-03-26 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
ES2408279B1 (es) 2011-12-15 2014-09-09 Universidad De Las Palmas De Gran Canaria Bacteria acido láctica probiótica
ITBG20120010A1 (it) 2012-02-24 2013-08-25 Milano Politecnico Dispositivo per l'addestramento chirurgico
ITMI20120471A1 (it) 2012-03-26 2013-09-27 Giovanni Mogna Composizione a base di ceppi di batteri bifidobacterium longum in grado di aiutare il prolungamento della vita
JP5792105B2 (ja) 2012-03-27 2015-10-07 森永乳業株式会社 ラクト−ｎ−ビオースｉの製造方法
EP2832859B1 (en) 2012-03-30 2018-07-25 Ajinomoto Co., Inc. Diabetes-inducible bacterium
WO2013154826A2 (en) 2012-04-11 2013-10-17 Nestec Sa Methods for diagnosing impending diarrhea
CN104507483A (zh) 2012-04-13 2015-04-08 波士顿学院理事会 益生元组合物及使用方法
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
WO2013171515A1 (en) 2012-05-18 2013-11-21 Genome Research Limited Methods and groups
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
CN110170050A (zh) 2012-06-04 2019-08-27 高拉夫·阿格拉沃尔 用于治疗克罗恩氏病和相关病况以及感染的组合物和方法
CN102743420A (zh) 2012-06-06 2012-10-24 上海交通大学 改善肠道菌群结构的方法及应用
WO2014001368A1 (en) 2012-06-25 2014-01-03 Orega Biotech Il-17 antagonist antibodies
CA2877811C (en) 2012-07-31 2019-07-23 Nestec S.A. Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (ibd)
WO2014019271A1 (en) 2012-08-01 2014-02-06 Bgi Shenzhen Biomarkers for diabetes and usages thereof
JP2015531770A (ja) 2012-08-29 2015-11-05 サリックス ファーマシューティカルズ，インコーポレイテッド 緩下剤組成物、ならびに便秘および関連胃腸疾患および症状を処置するための方法
US10220089B2 (en) 2012-08-29 2019-03-05 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
EP2894985A4 (en) 2012-09-13 2016-09-28 Massachusetts Inst Technology PROGRAMMABLE ACTIVE COMPOUND PROFILES OF TUMORED BACTERIA
KR101473058B1 (ko) 2012-09-19 2014-12-16 주식회사 쎌바이오텍 과민성 대장 증후군 예방 또는 치료용 조성물
CN103652322B (zh) 2012-09-21 2016-02-10 临沂思科生物科技有限公司 一种含乳酸菌的复合益生菌饲料添加剂的制备方法
EP3401396A1 (en) 2012-10-03 2018-11-14 Metabogen AB Treating or preventing atherosclerosis or associated diseases by beta-carotene
FR2997091B1 (fr) 2012-10-22 2016-05-06 Fond Mediterranee Infection Utilisation d'un compose antioxydant pour la culture de bacteries sensibles a la tension en oxygene
US20150290140A1 (en) 2012-10-30 2015-10-15 Nestec S.A. Compositions comprising microparticles and probiotics to deliver a synergistic immune effect
US9839657B2 (en) 2012-10-30 2017-12-12 Deerland Enzymes, Inc. Prebiotic compositions comprising one or more types of bacteriophage
EP2914135A1 (en) 2012-11-01 2015-09-09 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CN104955466A (zh) * 2012-11-23 2015-09-30 赛里斯治疗公司 协同细菌组合物和其制造方法和用途
US20150297642A1 (en) 2012-11-26 2015-10-22 Thomas Julius Borody Compositions for the restoration of a fecal microbiota and methods for making and using them
AU2013359212B2 (en) 2012-12-12 2017-01-19 Massachusetts Institute Of Technology Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
RU2721275C2 (ru) 2012-12-12 2020-05-18 Те Брод Инститьют, Инк. Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии
US20140193464A1 (en) 2013-01-08 2014-07-10 Imagilin Technology, Llc Effects of probiotics on humans and animals under environmental or biological changes
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
EP2958575B1 (en) 2013-02-22 2019-04-03 The Regents of The University of California Composition comprising lactobaccilus johnsonii 456 and its use in treating or preventing diseases
HK1214954A1 (zh) 2013-03-05 2016-08-12 格罗宁根大学 Faecalibacterium prausnitzii htf-f(dsm26943)在抑制炎症中的应用
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
EP2971148A4 (en) 2013-03-14 2016-08-17 Seres Therapeutics Inc METHODS OF DETECTING PATHOGENS AND ENRICHING FROM MATERIALS AND COMPOSITIONS
US9669059B2 (en) 2013-03-15 2017-06-06 University Of Florida Research Foundation, Incorporated Butyrogenic bacteria as probiotics to treat clostridium difficile
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
CN103142656A (zh) 2013-03-18 2013-06-12 广州知光生物科技有限公司 脆弱拟杆菌在制备防治结肠癌组合物中的应用
CN103156888A (zh) 2013-03-18 2013-06-19 广州知光生物科技有限公司 脆弱拟杆菌在制备治疗炎症性肠病组合物中的应用
CN103146620A (zh) 2013-03-25 2013-06-12 广州知光生物科技有限公司 具有益生菌特性的脆弱拟杆菌
JP2014196260A (ja) 2013-03-29 2014-10-16 公立大学法人奈良県立医科大学 慢性閉塞性肺疾患の予防又は治療用組成物
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
US9675648B2 (en) 2013-06-05 2017-06-13 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
WO2014201037A2 (en) 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
WO2014200334A1 (en) 2013-06-14 2014-12-18 N.V. Nutricia Synbiotic composition for treatment of infections in allergic patients
WO2015003001A1 (en) 2013-07-01 2015-01-08 The Washington University Methods for identifying supplements that increase gut colonization by an isolated bacterial species, and compositions derived therefrom
DK3016511T3 (da) 2013-07-02 2020-01-13 Austrianova Singapore Pte Ltd En fremgangsmåde til at frysetørre indkapslede celler, sammensætninger egnet til at fryse indkapslede celler og anvendelse af sådanne sammensætninger
WO2015003305A1 (zh) 2013-07-08 2015-01-15 吉瑞高新科技股份有限公司 电子烟盒
WO2015006355A2 (en) 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
WO2015013214A2 (en) 2013-07-21 2015-01-29 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
EP3027058B1 (en) 2013-07-31 2020-07-15 Incredible Foods, Inc. Encapsulated functional food compositions
WO2015021936A1 (en) 2013-08-16 2015-02-19 The University Of Hong Kong Method and compositions for treating cancer using probiotics cross-reference to related application
CN103509741B (zh) 2013-08-22 2015-02-18 河北农业大学 布劳特菌auh-jld56及其在牛蒡苷元转化中的应用
US10203329B2 (en) 2013-09-12 2019-02-12 The Johns Hopkins University Biofilm formation to define risk for colon cancer
WO2015057151A1 (en) 2013-10-18 2015-04-23 Innovafood Ab A nutritionally balanced composite meal for infants and small children and a method of producing said meal
PL229020B1 (pl) 2013-11-13 2018-05-30 Inst Biotechnologii Surowic I Szczepionek Biomed Spolka Akcyjna Nowy szczep Bifidobacterium breve
EP3074027B1 (en) 2013-11-25 2024-12-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CN103981117B (zh) 2013-12-24 2018-10-26 北京大伟嘉生物技术股份有限公司 一株高抗逆性屎肠球菌及其培养方法和应用
CN103981115B (zh) 2013-12-24 2018-10-26 北京大伟嘉生物技术股份有限公司 一株高抗逆性屎肠球菌及其应用
CN103820363B (zh) 2014-01-27 2016-02-24 福建省农业科学院生物技术研究所 一种屎肠球菌菌粉的制备与应用
CN103865846B (zh) 2014-02-27 2016-03-30 扬州绿保生物科技有限公司 一种屎肠球菌及其制备方法
CN103849590B (zh) 2014-03-25 2016-07-06 上海交通大学 一株耐酸短双歧杆菌BB8dpH及其应用
KR101683474B1 (ko) 2014-03-26 2016-12-08 주식회사 쎌바이오텍 과민성 대장 증후군 예방 또는 치료용 조성물
US9783858B2 (en) 2014-04-02 2017-10-10 Northwestern University Altered microbiome of chronic pelvic pain
US20150374760A1 (en) 2014-04-09 2015-12-31 Jose U. Scher Methods for treating psoriasis and psoriatic arthritis
KR101583546B1 (ko) 2014-04-09 2016-01-11 국립암센터 유전자 다형성을 이용한 소라페닙 치료에 대한 반응성 예측방법
WO2015156419A1 (en) 2014-04-10 2015-10-15 Riken Compositions and methods for induction of th17 cells
CN104195075B (zh) 2014-08-14 2017-04-19 生合生物科技股份有限公司 一种屎肠球菌ef08及包含它的饲料添加物和饲料
WO2015168534A1 (en) 2014-05-02 2015-11-05 Novogy, Inc. Therapeutic treatment of gastrointestinal microbial imbalances through competitive microbe displacement
WO2015169944A1 (en) 2014-05-08 2015-11-12 Panoptes Pharma Ges.M.B.H. Compounds for treating ophthalmic diseases and disorders
CN106687130B (zh) 2014-08-05 2020-01-21 深圳华大基因科技有限公司 真杆菌属在预防和治疗结直肠癌相关疾病中的用途
EP3188741A4 (en) 2014-08-28 2018-03-28 Yale University Compositions and methods for the treating an inflammatory disease or disorder
WO2016036615A1 (en) 2014-09-03 2016-03-10 California Institute Of Technology Microbe-based modulation of serotonin biosynthesis
CN104546935A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 多形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546933A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 粪拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546940A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 平常拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546942A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 多氏拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546934B (zh) * 2014-09-30 2019-04-09 深圳华大基因科技有限公司 粪副拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546932A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
US10046030B2 (en) 2014-10-07 2018-08-14 University Of Virginia Patent Foundation Compositions and methods for preventing and treating infection
BR112017008284A8 (pt) 2014-10-24 2023-04-11 Evolve Biosystems Inc Bifidobactérias ativadas e métodos para uso das mesmas
CA2966363A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
CA2966360C (en) 2014-10-30 2023-09-05 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
SG11201703395PA (en) 2014-10-31 2017-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
CN104435000A (zh) 2014-11-12 2015-03-25 江南大学 乳酸菌对支气管哮喘治疗中的应用
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2016086161A1 (en) 2014-11-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and gvhd
PT3065748T (pt) 2014-12-23 2018-02-28 4D Pharma Res Ltd Uma estirpe de bacteroides thetaiotaomicron e o seu uso na redução da inflamação
BR112017013274A2 (pt) 2014-12-23 2018-02-06 4D Pharma Research Limited polipeptídeo e imunomodulação
CN104560820B (zh) 2014-12-30 2017-10-20 杭州师范大学 屎肠球菌kq2.6及应用
JP6783247B2 (ja) 2015-01-23 2020-11-11 テンプル ユニヴァーシティ − オブ ザ コモンウェルス システム オブ ハイアー エデュケーション ガン予防における短鎖脂肪酸の使用
CN105982919A (zh) 2015-02-26 2016-10-05 王汉成 生物减速剂抗癌技术
WO2016139217A1 (en) 2015-03-04 2016-09-09 Ab-Biotics, S.A. Composition comprising anaerobically cultivated human intestinal microbiota
WO2016149449A1 (en) 2015-03-18 2016-09-22 Tufts University Compositions and methods for preventing colorectal cancer
CA2976956A1 (en) 2015-03-18 2016-09-22 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
BR112017025813A2 (pt) 2015-06-01 2018-08-14 Univ Chicago método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana
PL3307288T3 (pl) 2015-06-15 2019-12-31 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3360559T (pt) 2015-06-15 2020-01-06 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SMT201900588T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
CN105112333A (zh) 2015-08-31 2015-12-02 江南大学 一种具有良好肠道定殖能力的长双歧杆菌及筛选方法和应用
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
HUE036362T2 (hu) 2015-11-20 2018-07-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
AU2016361583B2 (en) 2015-11-25 2021-05-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
PL3313423T3 (pl) 2016-03-04 2019-09-30 4D Pharma Plc Kompozycje zawierające szczepy bakteryjne blautia do leczenia nadwrażliwości trzewnej
WO2017160711A1 (en) 2016-03-14 2017-09-21 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US20190314427A1 (en) 2016-12-16 2019-10-17 Evelo Biosciences, Inc. Methods of treating cancer using parabacteroides
WO2018112365A2 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
CN110191946A (zh) 2016-12-23 2019-08-30 学校法人庆应义塾 诱导cd8+t细胞的组合物及方法

Also Published As

Publication number Publication date
PT3549592T (pt) 2020-05-18
RS60245B1 (sr) 2020-06-30
SI3204025T1 (sl) 2020-02-28
LT3369425T (lt) 2021-04-12
AU2020241605A1 (en) 2020-10-29
BR112017025003A2 (pt) 2018-08-07
US20170354695A1 (en) 2017-12-14
EP3884953A1 (en) 2021-09-29
SI3549592T1 (sl) 2020-10-30
PL3369425T3 (pl) 2021-06-28
EP3549592A1 (en) 2019-10-09
CA2988686C (en) 2023-01-24
CY1122467T1 (el) 2021-01-27
HUE048823T2 (hu) 2020-08-28
LT3204025T (lt) 2019-12-10
SG10201912321RA (en) 2020-02-27
MD3369425T2 (ro) 2021-07-31
SMT201900665T1 (it) 2020-01-14
TWI782682B (zh) 2022-11-01
MA41060B1 (fr) 2019-11-29
JP2018199695A (ja) 2018-12-20
CA3182899A1 (en) 2016-12-22
MX2017016564A (es) 2018-02-21
HRP20192057T1 (hr) 2020-02-21
SMT202100204T1 (it) 2021-05-07
CL2017003191A1 (es) 2018-06-22
SG10201912322PA (en) 2020-02-27
HUE046221T2 (hu) 2020-02-28
IL255783A (en) 2018-01-31
RS59558B1 (sr) 2019-12-31
EP3549592B1 (en) 2020-02-12
DK3549592T3 (da) 2020-04-20
ES2863913T3 (es) 2021-10-13
CN108738311A (zh) 2018-11-02
TW201709918A (zh) 2017-03-16
PT3369425T (pt) 2021-03-08
CN108738311B (zh) 2020-11-03
PL3549592T3 (pl) 2020-11-16
JP2018502551A (ja) 2018-02-01
CO2017013231A2 (es) 2018-03-28
CY1124013T1 (el) 2022-05-27
IL255783B2 (en) 2023-06-01
DK3204025T3 (da) 2019-11-25
US11433106B2 (en) 2022-09-06
HRP20210246T1 (hr) 2021-05-28
SI3369425T1 (sl) 2021-03-31
LT3549592T (lt) 2020-05-25
ME03584B (me) 2020-07-20
DK3369425T3 (da) 2021-03-01
US20180344780A1 (en) 2018-12-06
ES2758679T3 (es) 2020-05-06
MA41060A (fr) 2017-08-15
MD3549592T2 (ro) 2020-07-31
CY1123196T1 (el) 2021-10-29
CA2988686A1 (en) 2016-12-22
EP3369425B1 (en) 2021-01-27
RS61538B1 (sr) 2021-04-29
AU2016278069A1 (en) 2017-12-14
ZA201707774B (en) 2018-11-28
ES2787523T3 (es) 2020-10-16
KR20180012845A (ko) 2018-02-06
US10493112B2 (en) 2019-12-03
HUE052737T2 (hu) 2021-05-28
PT3204025T (pt) 2019-12-16
CN112370468A (zh) 2021-02-19
HRP20200702T1 (hr) 2020-07-24
TWI739746B (zh) 2021-09-21
EA201890049A1 (ru) 2018-06-29
EP3204025B1 (en) 2019-09-11
EP3369425A1 (en) 2018-09-05
MD3204025T2 (ro) 2020-02-29
WO2016203220A1 (en) 2016-12-22
TW202200173A (zh) 2022-01-01
PL3204025T3 (pl) 2020-02-28
SMT202000227T1 (it) 2020-05-08
ME03784B (me) 2021-04-20
AU2016278069B2 (en) 2020-07-09
US20230310517A1 (en) 2023-10-05
EP3204025A1 (en) 2017-08-16
US20200138874A1 (en) 2020-05-07
PE20180266A1 (es) 2018-02-06

Similar Documents

Publication Publication Date Title
JP6389950B2 (ja) 細菌株を含む組成物
JP6375051B2 (ja) 細菌株を含む組成物
US11389493B2 (en) Compositions comprising bacterial strains
HK40023525A (en) Compositions comprising bacterial strains
OA18660A (en) Compositions comprising bacterial strains.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170428

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170428

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180820

R150 Certificate of patent or registration of utility model

Ref document number: 6389950

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250